Novavax Inc (NVAX) — 10-Q Filings

10-Q Filings (6)

• 10-Q Filing — May 6, 2026
• Novavax Q2 Revenue Plummets 92.8% Amid Fading Vaccine Demand — Aug 6, 2025 Risk: high
  NOVAVAX INC reported a significant decline in product revenue for the second quarter of 2025, falling to $150 million from $2.1 billion in the same period of 20
• Novavax Q1 2025: Balance Sheet Shifts — May 8, 2025 Risk: medium
  Novavax Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's revenue for the quarter was not explicitly stated in this excerpt, bu
• Novavax Q3 Revenue Flat, Net Loss Widens Amid Equity Offering — Nov 12, 2024 Risk: high
  For the third quarter of 2024, Novavax Inc. reported $157 million in revenue, a decrease from $159 million in the same period of 2023. The company's net loss wi
• Novavax Q2 Revenue Drops, Net Loss Narrows — Aug 8, 2024 Risk: medium
  Novavax Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's revenue for the quarter was $107.4 million, a decrease from $207.1 mi
• Novavax Inc. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: medium
  NOVAVAX INC (NVAX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Novavax Inc. reported financial results for the first quarter of 2024. The comp

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX